Acino ? Delivering Health
Acino ? Delivering Health
Acino ? Delivering Health
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Break-down of <strong>Acino</strong>’s revenue<br />
150<br />
135<br />
120<br />
105<br />
90<br />
75<br />
60<br />
45<br />
30<br />
15<br />
Proprietary products &<br />
contract manufacturing<br />
Total product sales in EUR million<br />
0<br />
2004 2005 2006 2007 2008 2009 2010 2011<br />
Peroral manufactured in Switzerland<br />
Peroral manufactured in India<br />
Contract manufacturing Peroral<br />
Parenteral<br />
Revenue of operating segments in 2011:<br />
– Renewed growth of Peroral +12%<br />
– Weaker period for Parenteral -9%<br />
Continued effort to optimize product mix<br />
Measures in manufacturing:<br />
– Focus on newer, higher margin<br />
products (example MUPS)<br />
– Discontinuation of betalactame<br />
production by the end of 2013<br />
– Aim to qualify Miesbach and<br />
Liesberg sites for FDA regulated<br />
markets<br />
Future: major part of revenue and profit<br />
growth to derive from Operating<br />
Segment Parenteral<br />
6
Change language